RICHMOND, Calif., June 29, 2017 /PRNewswire/
-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today
announced the appointment of Roger
Jeffs, Ph.D. and Joseph S.
Zakrzewski to the Company's Board of Directors. The
appointments bring extensive experience in therapeutic development
and commercialization to Sangamo's leadership.
"Roger and Joe bring years of leadership experience in drug
development, manufacturing, commercialization, and business
development, and we are delighted to welcome them both to Sangamo's
Board of Directors," said Dr. Sandy
Macrae, Chief Executive Officer of Sangamo. "Sangamo is at
an important inflection point, and their deep knowledge and
expertise will be highly valuable as we accelerate the clinical
translation of our ground-breaking science into genomic medicines
for patients."
Dr. Jeffs currently serves as a Senior Advisor to United
Therapeutics Corp., where he worked for 18 years, most recently as
President and co-CEO. He has over 25 years of experience in the
biopharmaceutical industry in R&D, clinical development,
regulatory and medical affairs. While at United Therapeutics, Dr.
Jeffs led the clinical development, regulatory approval and
commercialization of six rare disease products. Prior to joining
United Therapeutics, he held positions in clinical development at
Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs currently serves
as a member of the board of directors of Axsome Therapeutics and
Dova Pharmaceuticals. He received a B.A. in Chemistry from
Duke University and his Ph.D. in
Pharmacology from the University of North
Carolina.
Mr. Zakrzewski has over 25 years of experience in the
biopharmaceutical industry with senior leadership experience in
R&D, supply chain and manufacturing operations, business
development and commercialization. From 2010 through 2013, he was
Chairman and CEO of Amarin Pharmaceuticals, where he led the
development and commercialization of the company's first product,
Vascepa. Mr. Zakrzewski previously served as a Venture Partner with
Orbimed Advisors, a venture capital firm, and as Chairman,
President and CEO of Xcellerex, a privately held company focused on
the commercialization of its proprietary manufacturing technology
for biotherapeutics and vaccines. Earlier, he served as COO of
Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline
in 2007 and held various executive positions at Eli Lilly &
Company in the areas of R&D, manufacturing, finance and
business development. Mr. Zakrzewski currently serves as a member
of the board of directors of various public and private companies,
including Acceleron Pharma, Amarin Pharmaceuticals Insulet
Corporation and Onxeo SA where he serves as Chairman. Mr.
Zakrzewski received a B.S. in Chemical Engineering and an M.S. in
Biochemical Engineering from Drexel
University, and an M.B.A. in Finance from Indiana University.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc.
is focused on translating ground-breaking science into genomic
therapies that transform patients' lives using the company's
industry leading platform technologies in genome editing, gene
therapy, gene regulation and cell therapy. The Company is
conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia
B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an
exclusive, global collaboration and license agreement with Pfizer
Inc. for gene therapy programs for Hemophilia A, with Bioverativ
Inc. for hemoglobinopathies, including beta thalassemia and sickle
cell disease, and with Shire International GmbH to develop
therapeutics for Huntington's
disease. In addition, Sangamo has established strategic
partnerships with companies in non-therapeutic applications of its
technology, including Sigma-Aldrich Corporation and Dow
AgroSciences. For more information about Sangamo, visit
www.sangamo.com.
Forward-Looking Statements
This press release may
contain forward-looking statements based on Sangamo's current
expectations. These forward-looking statements include, without
limitation, the Company's plans for and pace of development and
potential commercialization of its product candidates. Actual
results may differ materially from these forward-looking statements
due to a number of factors, including risks related to the ability
of the Company to successfully develop and commercialize any of its
product candidates. Additional risks and uncertainties relating to
Sangamo and its business can be found under the heading "Risk
Factors" in Sangamo's most recent Quarterly Report on Form 10-Q for
the quarter ended March 31, 2017,
which was filed with the SEC on May 10,
2017. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this
press release. Sangamo assumes no obligation to update the
forward-looking information contained in this press
release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-appoints-roger-jeffs-phd-and-joseph-s-zakrzewski-to-its-board-of-directors-300482040.html
SOURCE Sangamo Therapeutics, Inc.